Form 4: Tourmaline Bio CFO Acquires Stock Options

Ryan F. Robinson, CFO of Tourmaline Bio, Inc., was granted employee stock options for 58,000 shares on January 27, 2025.

Summary

• Ryan F. Robinson, the Chief Financial Officer of Tourmaline Bio, Inc., was granted employee stock options.
• The transaction occurred on January 27, 2025.
• Robinson acquired options for 58,000 shares of common stock at an exercise price of $17.
• The options vest over time, starting with 25% on January 27, 2026, and the remainder in 36 equal monthly installments, contingent upon continued service.
• The options expire on January 26, 2035.
• Following the transaction, Robinson directly owns options for 58,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance and retention.

Stakeholder Impact

• The stock option grant could positively impact shareholders by incentivizing the CFO to improve company performance.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates